Furthermore, silibinin modulates lung cancer (H3122 and H2228) cells by enhancing the therapeutic effects of nintedanib, brigatinib, and lorlatinib through the inhibition of STAT3 activity [902, 903]. This evidence concerns the gene STAT3 and lung carcinoma.